Neurogene (NGNE) Shares Outstanding (Weighted Average) (2013 - 2026)

Neurogene has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 67.65% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (down 67.65% YoY), and the FY2025 full-year result was $21.3 million, up 21.4% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $6.8 million, down from $21.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $21.3 million in Q4 2025, with the low at $439073.0 in Q2 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $9.6 million across 5 years, with a median of $6.8 million in 2025.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) plunged 96.53% — and 2024, when it surged 3471.51%.
• Neurogene's Shares Outstanding (Weighted Average) stood at $11.1 million in 2022, then plunged by 95.55% to $491867.0 in 2023, then surged by 3471.51% to $17.6 million in 2024, then gained by 21.4% to $21.3 million in 2025, then slumped by 68.15% to $6.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $6.8 million (Q1 2026), $21.3 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.